Nicholas R. Casewell

2026 United Kingdom Award Finalist — Faculty

Nicholas R. Casewell

Current Position:
Professor of Tropical Disease Biology and Director of the Centre for Snakebite Research & Interventions

Institution:
Liverpool School of Tropical Medicine

Discipline:
Biomedical Engineering & Biotechnology

Recognised for: Using molecular approaches to characterise the genes associated with snake venom toxins, identify new treatment strategies for snakebite, and build capacity in local communities affected by this neglected disease.

Areas of Research Interest and Expertise:
Venom, snakebite, therapeutics, tropical diseases, toxinology

Previous Positions:

  • BSc, The University of Liverpool
  • PhD, Bangor University, (Advisor: Wolfgang Wüster)
  • Postdoctoral Researcher, Liverpool School of Tropical Medicine & MicroPharm Ltd, (Advisor: Robert Harrison)
  • Natural Environment Research Council (NERC) Postdoctoral Research Fellow, Bangor University
  • Career Track Lecturer, Liverpool School of Tropical Medicine
  • Wellcome Trust and Royal Society Sir Henry Dale Research Fellow, Liverpool School of Tropical Medicine
  • Senior Lecturer, Liverpool School of Tropical Medicine
  • Deputy Head of Department of Tropical Disease Biology, Liverpool School of Tropical Medicine
  • Interim Head of Department of Tropical Disease Biology, Liverpool School of Tropical Medicine

Research Summary:

Every year, hundreds of thousands of people experience severe or fatal consequences from snakebites. Therapeutic options are limited and often difficult to access in vulnerable rural areas. Toxinologist Nicholas R. Casewell, PhD, is applying state-of-the-art methods, including novel venom gland organoids, to investigate the composition and evolution of snake venom toxins at both the molecular and functional levels. Using AI and bioinformatic-informed approaches, Casewell is working to develop and validate more potent and specific combination therapies that can be administered widely to reduce immediate disease severity. In collaboration with affected communities, Casewell aims to establish the efficacy of new therapeutics via clinical trials, leading the way for improved patient outcomes and global impact.

“Using a multi-disciplinary approach, our research seeks to understand the diverse and variable nature of snake venoms, so that we can develop broadly-effective, affordable, and life-saving therapies for snakebite patients across the globe.”

Key Publications:

  1. T.Y. Du, S.R. Hall, F. Chung, S. Kurdyukov, E. Crittenden, K. Patel, C.A. Dawson, A.P. Westhorpe, K.E. Bartlett, S.A. Rasmussen, C.L. Moreno, C.E. Denes, L-O. Albulescu, A.E. Marriott, J.P. Mackay, M.C. Wilkinson, J.M. Gutiérrez, N.R. Casewell, G.G. Neely. 2024. Molecular dissection of cobra venom highlights heparinoids as an effective snakebite antidote. Science Translational Medicine. 2024.

  2. T.D. Kazandjian, D. Petras, S.D. Robinson, J. van Thiel, H.W. Greene, K. Arbuckle, A. Barlow, D.A. Carter, R.M. Wouters, G. Whiteley, S.C. Wagstaff, A.S. Arias, L-O. Albulescu, A. Plettenberg Laing, C. Hall, A. Heap, S. Penrhyn-Lowe, C.V. McCabe, S. Ainsworth, R.R. da Silva, P.C. Dorrestein, M.K. Richardson, J.M. Gutiérrez, J.J. Calvete, R.A. Harrison, I. Vetter, E.A.B. Undheim, W. Wüster, N.R. CasewellConvergent evolution of pain-inducing defensive venom components in spitting cobras. Science. 2021.
  3. Y. Post, J. Puschof, J. Beumer, H.M. Kerkkamp, J. Slagboom, B. de Barbanson, N.R. Wevers, T. Olivier, X. Spijkers, T.D. Kazandjian, S. Ainsworth, C. Lopez Iglesias, W. van de Wetering, M.C. Heinz, R.L. van Ineveld, R.G.D.M. van Kleef, H. Begthel, J. Korving, Y.E. Bar-Ephraim, W. Getreuer, A. Rios, R.H.S. Westerink, H.J.G. Snippert, A. van Oudenaarden, P. Peters, F.J. Vonk, J. Kool, M.K. Richardson, N.R. Casewell, H. Clevers. Snake venom gland organoids. Cell. 2020.
  4. L-O. Albulescu, C. Xie, S. Ainsworth, J. Alsolaiss, E. Crittenden, C.A. Dawson, R. Softley, K.E. Bartlett, R.A. Harrison, J. Kool, N.R. CasewellA therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. Nature Communications. 2020.

Other Honors:

2025 Finalist, The Blavatnik Awards for Young Scientists in the United Kingdom
2024 Principle Investigator, Research Grant, Medical Research Council
2024 Principle Investigator, Clinical Trial Grant, Open Philanthropy
2022 Principle Investigator, Research Grant, Leverhulme Trust
2021 Principle Investigator, Research Grant, Wellcome Trust
2021 Committee member of the UK Health Security Agency Expert Group on Antivenoms
2019 Young Investigator Award, Toxins journal
2018 Principle investigator, Research Grant, Medical Research Council
2018 Member of the Executive Committee and Secretary of the European Section of the International Society on Toxinology
2016 Sir Henry Dale Research Fellowship, Wellcome Trust and the Royal Society
2012 NERC Postdoctoral Research Fellowship, Natural Environment Research Council

In the Media:

Website